spacer
home > ebr > winter 2009 > targeting tumours
PUBLICATIONS
European Biopharmaceutical Review

Targeting Tumours

With existing monoclonal antibody drugs for the treatment of cancer having achieved blockbuster status, what further benefits can antibodies bring to the field of cancer therapeutics? For example, can the success of the anti-angiogenic Avastin® (bevacizumab, Roche) be equalled or bettered? The potential of targeting alternative or additional proteins involved in generating new blood vessels has been recognised; a deal has been secured around an antibody in development that binds placental growth factor (PlGF). Other treatment strategies in which antibodies are used to inhibit protein kinase function or induce cell death are also being developed.

THE ESTABLISHMENT OF mAbs

It is now over 10 years since the first monoclonal antibody (mAb) drug was launched onto the market to treat cancer. Since then, the market for this class of drugs has grown rapidly, driving new growth in the cancer and pharmaceutical market as a whole. In 2006, four of the top 10 innovative cancer treatments were monoclonal antibodies: Rituxan/ MabThera (rituximab), Herceptin (trastuzumab), Avastin (bevacizumab) and Erbitux (cetuximab). Together, these treatments achieved sales figures in excess of $10 billion (1).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Mats Hellström is a Senior Principal Scientist at BioInvent International and is responsible for preclinical research in the areas of angiogenesis, stroma biology and oncology. Prior to joining BioInvent, Mats was CEO of the drug discovery company, AngioGenetics AB. He has been a researcher at the Karolinska Institutet and has a PhD from Gцteborg University, Sweden.

Björn Frendéus is a Senior Principal Scientist at BioInvent International, responsible for preclinical research in the areas of inflammation and immunology and is also involved in target discovery. Before joining BioInvent, Bjцrn was a researcher at the Department of Clinical Immunology at Lund University in Sweden where he earned his PhD.

spacer
Mats Hellström
spacer
spacer
spacer
Björn Frendéus
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

KITE’S CAR T-CELL THERAPY TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) RECEIVES POSITIVE CHMP OPINION IN RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA

Stockley Park, UK – 22 July 2022 – Kite, a Gilead Company, today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and above with relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukaemia (ALL). If approved, brexucabtagene autoleucel will be the first and only CAR T-cell therapy for this population of patients who have limited treatment options. Half of adults with ALL will relapse, and median overall survival (OS) for this group is only approximately eight months with current standard-of-care treatments.[1],[2]
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement